Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 10770 Wateridge Circle Suite 200 Suite 200 SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.maravai.com |
IR: | See website |
Key People | ||
Robert Andrew Eckert Chairman of the Board | William Martin Chief Executive Officer, Director | Kevin M. Herde Chief Financial Officer |
Andrew Burch President - Nucleic Acid Production | Rebecca Buzzeo Executive Vice President, Chief Commercial Officer | Peter Michael Leddy Chief Administrative Officer |
Kurt Oreshack General Counsel, Secretary | Christine Dolan Chief Operating Officer - Biologics Safety Testing |
Business Overview |
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. |
Financial Overview |
For the nine months ended 30 September 2024, Maravai Lifesciences Holdings Inc revenues decreased 6% to $202.8M. Net loss increased from $13.1M to $118.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase of 62% to $28.6M (expense), Stock-based Compensation in R&D increase of 92% to $3.7M (expense). |
Employees: | 580 as of Sep 30, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,397M as of Sep 30, 2024 |
Annual revenue (TTM): | $276.92M as of Sep 30, 2024 |
EBITDA (TTM): | $13.13M as of Sep 30, 2024 |
Net annual income (TTM): | -$224.66M as of Sep 30, 2024 |
Free cash flow (TTM): | -$11.72M as of Sep 30, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 252,527,585 as of Nov 7, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |